We claim:

1. The use of a film coating consisting of

a) polyvinyl acetate
b) hydrophilic additives
c) other conventional coating ingredients
d) and, where appropriate, a physiologically tolerated acid

as taste-masking coating for oral dosage forms.

2. The use of a film coating as claimed in claim 1, wherein the hydrophilic additives are selected from the group of film-forming water-soluble polymers and/or from the group of water-insoluble but swelling polymers and/or from the group of very fine-particle dusting agents.

3. The use of a film coating as claimed in either of claims 1 or 2, wherein the film-forming water-soluble polymers are selected from the group of poly(vinyllactams), vinylpyrrolidone/vinyl acetate copolymers, polyvinyl alcohols or cellulose derivatives, as water-insoluble but highly swelling polymers crosslinked poly(vinyllactams), cellulose or cellulose derivatives or starch derivatives and as fine-particle dusting agents highly disperse silicas, fine-particle starches, fine-particle celluloses or fine-particle salts of phosphoric acid.

4. The use of the film coating as claimed in any of claims 1 to 3, wherein the ratio by weight amounts to

a) 50 to 90% polyvinyl acetate
b) 10 to 75% hydrophilic additives
c) 0 to 20% other conventional coating ingredients
d) and, where appropriate, 0 to 30% of a physiologically tolerated acid.

5. The use of the film coating as claimed in any of claims 1 to 4, wherein the ratio by weight of the coating material a : b is from 1 : 0.1 to 1 : 0.75.

6. The use of the film coating as claimed in any of claims 1 to 5, wherein the taste-masking coating comprises 5 to 25% by weight based on the total weight of the coated shaped articles.

7. An oral dosage form with an active ingredient-containing core and a taste-masking coating consisting of

   a) polyvinyl acetate
   b) hydrophilic additives
   c) other conventional coating ingredients
   d) and, where appropriate, a physiologically tolerated acid or base.

8. An oral dosage form as claimed in claim 7, which comprises the following substances based on the weight of the core

   a) 30 to 98% active ingredient
   b) 2 to 70% binder
   c) 0.1 to 5.0% emulsifier and, where appropriate,
   d) 2 to 30% disintegrant
   e) and, where appropriate, 0 to 20% of a physiologically tolerated acid or base.

9. An oral dosage form as claimed in either of claims 7 or 8, which comprises as active ingredients food supplements or additives, vitamins, minerals or trace elements or active pharmaceutical ingredients.

10. An oral dosage form as claimed in any of claims 7 to 9, which comprises active pharmaceutical ingredients as active ingredients.

11. An oral dosage form as claimed in either of claims 7 or 10, which comprises as active ingredient acetaminophen, ibuprofen, naproxen, chlorpheniramine, dextromethorphan, acetylsalicylic acid, loperamide, pseudoephedrine, diphenhydramine, famotidine, cimetidine, ranitidine, nizatidine, salts or combinations thereof.

12. A taste-masked oral dosage form obtainable by compression of at least one preparation as claimed in claims 7 to 11 with conventional tablet excipients.

13. A taste-masked oral dosage form as claimed in claim 12, wherein from 0 to 40% of a physiologically tolerated acid or base are added to the tablet mixture.

14. A process for producing a taste-masked oral dosage form comprising the steps

a) production of medicinal substance-containing shaped articles from active ingredient, binder, disintegrant and emulsifier,

b) coating of medicinal substance-containing shaped articles with the film coating as claimed in claim 1 and

c) compression of the coated medicinal substance with conventional tablet excipients.